XRHealth Receives Patent to Measure Sway & Conduct Fall Risk Assessment in Virtual Reality & Augmented Reality Therapy

XRHealth, the leader in extended reality and therapeutic telehealth applications, announces today that they received a patent to measure sway and conduct a fall risk assessment using virtual reality and augmented reality therapy.

According to the CDC, one out of five falls results in serious complications like broken bones or head injury. With the new capability, XRHealth can assess the risk of elderly patients’ likelihood of falling, potentially preventing a debilitating injury.

The patent is entitled “Assessing Postural Sway in Virtual Reality or Augmented Reality.” Sway is measured by using a VR/AR platform to measure positional data from a headset or hand sensors. The positional data then determines the center of mass. When the patient enters the virtual/augmented reality environment, it simulates a situation where the user is unbalanced. The data on position and center of mass is then sent to a server to determine if the person poses a risk for falling.

Three million elderly people are sent to emergency rooms each year to treat injuries from falls and 95% of hip fractures are a result of falls. “When treating elderly patients, the ability to measure sway accurately in an AR/VR therapeutic process can potentially prevent falls that can result in long-term disabilities,” said Eran Orr, CEO of XRHealth. “The advantage of using XR to measure sway is that patients can do this from the comfort of their home, during routine extended reality therapy.”

XRHealth has virtual clinics throughout the United States that treat patients remotely with VR/AR-based therapy while they are examined by a licensed XRHealth therapist. The XRHealth platform combines FDA-registered medical applications with advanced data analytics, providing a comprehensive solution for therapists and patients while collecting and analyzing patient interactions with virtual objects in virtual environments.

 

SourceXRHealth

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”